Scarica l'app Stockscreener
155.00
1.47%
2.25
Dopo l'orario di chiusura:
155.00
Precedente Chiudi:
$152.75
Aprire:
$153.34
Volume 24 ore:
2.19M
Relative Volume:
2.37
Capitalizzazione di mercato:
$7.63B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
19.35
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+3.11%
1M Prestazione:
-2.76%
6M Prestazione:
+1.19%
1 anno Prestazione:
-23.83%
Intervallo 1D:
$151.56
$155.43
Intervallo di 1 settimana:
$145.99
$155.43
Portata 52W:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
155.00 | 7.33B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
484.79 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.14 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
664.16 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
120.29 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.23 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Do Charles River (CRL) Earnings Trends Reveal Shifting Priorities in Its Advanced Therapeutics Ambitions? - simplywall.st
5 Revealing Analyst Questions From Charles River Laboratories’s Q2 Earnings Call - Yahoo Finance
Stock Analysis | Charles River Laboratories International OutlookMixed Technical Signals and Strong Fundamentals - AInvest
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - MSN
Interpreting Charles River (CRL) International Revenue Trends - Yahoo Finance
Charles River Laboratories International Inc. Recovery Linked to Earnings SurprisePattern Alert With ROI Driven Strategy Shared - metal.it
Charles River Laboratories Q2 2025 Earnings Call Transcript Summary - AInvest
Charles River Laboratories International Inc's Q2 2025 Financials and Strategic Direction: A SWOT Analysis - AInvest
Charles River Laboratories Reports Q2 2025 Earnings - The Globe and Mail
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Why Charles River Laboratories International Inc. stock attracts strong analyst attentionWeekly Hot Picks With Buy Confidence Released - beatles.ru
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River (CRL) Q2 EPS Jumps 11% - The Motley Fool
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Laboratories Q2 2025 Earnings Call Transcript Review - AInvest
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 - Yahoo Finance
Charles River Labs Q2 2025 slides: Beats expectations, raises guidance amid stabilizing demand - Investing.com Canada
Charles River Laboratories Announces Second-Quarter 2025 Results - BioSpace
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Updated - MarketScreener
Charles River Laboratories Reports Q2 2025 Revenue of $1.03 Bill - GuruFocus
Charles River Labs soars 6.9% after crushing Q2 earnings expectations By Investing.com - Investing.com South Africa
Charles River Labs soars 6.9% after crushing Q2 earnings expectations - Investing.com
Charles River Laboratories earnings beat by $0.62, revenue topped estimates - Investing.com Canada
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
How volatile is Charles River Laboratories International Inc. stock compared to the marketBuild wealth steadily with proven strategies - Jammu Links News
Charles River Laboratories International Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Jammu Links News
What is Charles River Laboratories International Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Is it the right time to buy Charles River Laboratories International Inc. stockIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Charles River Laboratories International Inc. stockRobust investment performance - Jammu Links News
How strong is Charles River Laboratories International Inc. company’s balance sheetMarket-leading profit generation - Jammu Links News
What are Charles River Laboratories International Inc. company’s key revenue driversAchieve breakthrough gains with expert advice - Jammu Links News
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.96%
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):